X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cyrano intends to use the proceeds to advance FLAVOR, its Phase 2, double-blind, randomized clinical trial of CYR-064, an intranasal theophylline spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection.
Lead Product(s): Theophylline
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CYR-064
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: DeepWork Capital
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024
Details:
CYR-064 is a novel, soft-mist nasal-spray product candidate, being developed for the treatment of post-viral smell loss (Hyposmia). It has the potential to become the first pharmaceutical product to restore the senses of smell and taste in patients.
Lead Product(s): CYR-064
Therapeutic Area: Neurology Product Name: CYR-064
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
CYR-064 is a soft mist nasal spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection (post-viral hyposmia).
Lead Product(s): CYR-064
Therapeutic Area: Neurology Product Name: CYR-064
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company’s board of directors.
Lead Product(s): CYR-064
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CYR-064
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Remiges Ventures
Deal Size: $12.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
